EyePoint Pharmaceuticals will present two abstracts supporting its YUTIQ 0.18 mg three-year micro-insert for posterior segment uveitis at the 2018 Association for Research in Vision and Ophthalmology Meeting.
Here are three quick facts.
1. Eric Suhler, MD, of VA Portland (Ore.) Health Care System and Portland-based Casey Eye Institute-OHSU will present an abstract on the safety and efficacy of YUTIQ for treating non-infectious posterior segment uveitis, and pooled results of two Phase 3 trials. The paper presentation is scheduled for May 3.
2. Quan Nguyen, MD, of the Byers Eye Institute in Palo Alto, Calif., will present an abstract on controlling posterior segment uveitic recurrences and results from a Phase 3 study involving subjects with chronic non-infectious uveitis. The poster presentation is scheduled for April 29.
3. The FDA is reviewing the ophthalmic pharmaceutical company's new drug application for YUTIQ for the treatment of noninfectious posterior segment uveitis. The approval deadline is Nov. 5.
"We believe that, if approved, YUTIQ has the potential to become an important new treatment option for the thousands of patients suffering from this disease, which is the third leading cause of blindness," President and CEO Nancy Lurker said.